亚洲av最新在线网址,久久精品免费一区二区,自拍区小说区图片区亚洲

首頁(yè)> 產(chǎn)品列表> 雜環(huán)化合物吲哚類雜環(huán)>

SC-2001

NMR下載 COA and HPLC MSDS下載
names：
5-Bromo-2-[4-methoxy-5-(2H-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-yl]-1H-indole
CAS號(hào)：
1383727-17-0
MDL Number：
MF(分子式)： C18H14BrN3O MW(分子量)： 368.234
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	5-Bromo-2-[4-methoxy-5-(2H-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-yl]-1H-indole
英文別名	SC-2001; SC 2001; SC2001.
CAS號(hào)	1383727-17-0
Inchi	InChI=1S/C18H14BrN3O/c1-23-18-10-16(22-17(18)9-13-3-2-6-20-13)15-8-11-7-12(19)4-5-14(11)21-15/h2-10,21-22H,1H3/b13-9+
InchiKey	MJCQSMDIFFNYRS-UKTHLTGXSA-N
分子式 Formula	C18H14BrN3O
分子量 Molecular Weight	368.234
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	SC-2001(CAS:1383727-17-0):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	SC-2001 is a MCL-1 inhibitor. SC-2001 is an Obatoclax analog that inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695. PubMed PMID: 27086916; PubMed Central PMCID: PMC5564524.

[2]Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis. 2014 Dec;35(12):2807-14. doi: 10.1093/carcin/bgu210. Epub 2014 Oct 16. PubMed PMID: 25322871.

[3] Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18. PubMed PMID: 25047655; PubMed Central PMCID: PMC4198826.

[4] Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget. 2014 Jul 15;5(13):4909-19. PubMed PMID: 24952874; PubMed Central PMCID: PMC4148109.

[5] Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2014 Jul;146(1):71-84. doi: 10.1007/s10549-014-3000-0. Epub 2014 Jun 6. PubMed PMID: 24903225.

6: Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol. 2012 Aug 1;84(3):268-77. doi: 10.1016/j.bcp.2012.04.023. Epub 2012 May 9. PubMed PMID: 22580047.7: Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Lett. 2012 Aug 1;321(1):27-35. doi: 10.1016/j.canlet.2012.03.023. Epub 2012 Mar 28. PubMed PMID: 22465052.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開